RER1.F Recordati Industria Chimica e Farmaceutica S.p.A
- Market cap
- EUR 10.9B
- P/E
- 20.9x
- P/B
- 5.12x
- ROE
- 23.2%
- Dividend yield
- 2.45%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is RER1.F undervalued?
Graham numberRER1.F trades 118.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Recordati Industria Chimica e Farmaceutica S.p.A fundamental analysis
No fundamental analysis for Recordati Industria Chimica e Farmaceutica S.p.A yet.
Recordati Industria Chimica e Farmaceutica S.p.A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Recordati Industria Chimica e Farmaceutica S.p.A
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops Maapliv for maple syrup urine disease; Isturia for endogenous Cushing's syndrome; Cystadrops treatment of the ocular m…
Full company profileRecordati Industria Chimica e Farmaceutica S.p.A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Recordati Industria Chimica e Farmaceutica S.p.A annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.15B | 1.29B | 1.35B | 1.48B | 1.45B | 1.58B | 1.85B | 2.08B | 2.34B | 2.62B | 2.80B |
| Gross Profit | 793M | 905M | 957M | 1.04B | 1.04B | 1.15B | 1.29B | 1.42B | 1.60B | 1.79B | 2.00B |
| Operating Income | 340M | 409M | 446M | 470M | 474M | 505M | 494M | 566M | 660M | 720M | 857M |
| EBITDA | - | 451M | 497M | 543M | 567M | 578M | 559M | 709M | 796M | 887M | 1.02B |
| Net Income | 237M | 289M | 312M | 369M | 355M | 386M | 312M | 389M | 417M | 444M | 543M |
| EPS | - | 1.39 | 1.53 | 1.79 | 1.72 | 1.87 | 1.52 | 1.89 | 2.02 | 2.17 | 2.61 |
| Balance Sheet | |||||||||||
| Total Assets | 1.56B | 2.06B | 2.16B | 2.81B | 2.71B | 2.82B | 4.00B | 4.21B | 5.13B | 5.25B | 5.46B |
| Total Liabilities | 657M | 1.03B | 1.20B | 1.61B | 1.44B | 1.43B | 2.45B | 2.52B | 3.26B | 3.33B | 3.12B |
| Shareholders' Equity | 904M | 1.03B | 963M | 1.20B | 1.28B | 1.38B | 1.55B | 1.69B | 1.88B | 1.92B | 2.34B |
| Cash & Short-term Investments | 117M | 273M | 172M | 141M | 188M | 245M | 285M | 222M | 322M | 429M | 503M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 255M | 273M | 358M | 319M | 404M | 492M | 462M | 485M | 570M | 597M | 651M |
| Capital Expenditure | 36.9M | 14.6M | 19.4M | 22.1M | 21.3M | 21.9M | 23.9M | 383M | 851M | 85.1M | 160M |
| Free Cash Flow | - | -48.0M | 287M | -124M | 272M | 404M | 365M | 102M | -281M | 512M | 490M |
| Ratios | |||||||||||
| ROE | 26.3% | 28.1% | 32.4% | 30.8% | 27.8% | 27.9% | 20.2% | 23.1% | 22.2% | 23.1% | 23.2% |
| ROA | 15.2% | 14.0% | 14.4% | 13.1% | 13.1% | 13.7% | 7.8% | 9.2% | 8.1% | 8.4% | 9.9% |
| Net Profit Margin | 20.6% | 22.4% | 23.1% | 24.9% | 24.5% | 24.4% | 16.9% | 18.7% | 17.8% | 16.9% | 19.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Recordati Industria Chimica e Farmaceutica S.p.A dividends
- Dividend yield
- 2.45%
- Forward dividend
- 1.42 EUR
- Payout ratio
- 60.3%
- Ex-dividend date
- May 18, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 268M | 1.31 | 60.3% |
| 2024 | EUR 254M | 1.23 | 60.9% |
| 2023 | EUR 246M | 1.19 | 63.2% |
| 2022 | EUR 231M | 1.12 | 73.8% |
| 2021 | EUR 217M | 1.05 | 56.2% |
| 2020 | EUR 213M | 1.03 | 59.9% |
| 2019 | EUR 191M | 0.93 | 51.8% |
| 2018 | EUR 179M | 0.88 | 57.3% |
| 2017 | EUR 160M | 0.77 | 55.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Recordati Industria Chimica e Farmaceutica S.p.A
- Insiders 46.82%
- Institutions 35.15%
- Public & others 18.03%
- Shares outstanding 208M
- Free float 101M
Recordati Industria Chimica e Farmaceutica S.p.A company profile
- Company name
- Recordati Industria Chimica e Farmaceutica S.p.A
- Ticker
- RER1.F
- ISIN
- IT0003828271
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 4,700
- Fiscal year end
- December
- Address
- Via Matteo Civitali,1, Milan, MI, Italy, 20148
- Phone
- 39 02 487871
- Website
- recordati.com
About Recordati Industria Chimica e Farmaceutica S.p.A
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops Maapliv for maple syrup urine disease; Isturia for endogenous Cushing's syndrome; Cystadrops treatment of the ocular manifestations of cystinosis; Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency; Qarziba for neuroblastoma patients and patients with relapsed or refractory neuroblastoma; and Fotivda for renal cell carcinoma. It also develops Sylvant for idiopathic multicentric castleman diseases; Caphosol for oral mucositis; ENJAYMO for hemolysis in adults with cold agglutinin disease; Zanidip, Zanipress, Vazkepa, and Logimax for hypertension; Urorec and Avodart for symptoms of benign prostatic hyperplasia; and Livazo for dyslipidemia; Combodart/Duodart; Seloken for angina pectoris, myocardial infarction and cardiac rhythm disorders, as well as hypertension and functional heart disorders. In addition, the company offers Procto-Glyveno for internal and external hemorrhoids; Polydexa, Isofra, and Otofa for ear, nose and throat infections; Isturisa, for Cushing's syndrome; Normosang, human hemin; Juxtapid, homozygous familial hypercholesterolemia;Ledaga, mycosis fungoides, T-cell cutaneous lymphoma;Tergynan, an anti-infective for gynecological infections; CitraFleet and Phosphosoda as bowel cleansers; Lomexin for gynecological and dermatological infections; Hexaspray, treatments for the oral cavity; Magnesio Supremo, a dietary supplement; Reaglia for schizophrenia; Eligard for hormone-dependent prostate cancer; and pasireotide in Phase II trial for patients with post-bariatric hypoglycemia, as well as other products. The company was founded in 1926 and is headquartered in Milan, Italy.
Recordati Industria Chimica e Farmaceutica S.p.A management
10- Dr. Robert Koremans M.D.CEO & Director · born 1962
- Ms. Cathrin PettyExecutive Director · born 1973
- Mr. Giampiero MazzaExecutive Director · born 1969
- Mr. Michael McClellanChief Financial Officer · born 1971
- Ms. Eugenia Shen LitzVP & Head of Investor Relations
- Ms. Bibianne BonGroup Chief Legal Officer
- Ms. Laura ContiGroup Communications Director
- Mr. Gabriele FinziExecutive Vice President of Corporate Development, Licensing & Innovation
- Ms. Alessandra AbateGroup Chief People & Culture Officer
- Mr. Alberto MartinezExecutive Vice President of Specialty & Primary Care Business Unit